Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1999-03-16
2000-10-24
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514 77, 514 78, 514529, 514557, 562566, A01N 5700
Patent
active
061367966
ABSTRACT:
The invention relates to a pharmaceutically acceptable prodrug which is a covalent conjugate of a pharmacologically active compound and an intracellular transporting adjuvant, characterized by the presence of a covalent bond which is scission-sensitive to intracellular enzyme activity. The prodrug may be used in a technique for treating a condition or disease in a human related to supranormal intracellular enzyme (.e.g. phospholipase and/or esterase) activity, whereby on administering it to a human having such condition or disease, the bond is broken in response to such activity, and the pharmacologically active compound accumulates selectively within cells having such supranormal intracellular enzyme activity. Exemplary conjugates are esters of the carboxylic function in the formula, with e.g. heptanoyl-sn-3-glycerophosphoryl-choline or octanoyl-sn-3-glycerophosphoryl-choline.
REFERENCES:
patent: 5149794 (1992-09-01), Yatvin
patent: 5227514 (1993-07-01), Meul et al.
Hostetler JBC 266 #18, p 11714-11717, Jun. 1991.
Vaizoglu Eu. J. of Pharmaceutics & Biopharmaceutics. 38 #1 p 1-6, Feb. 1992.
Sinkula J. Pharmaceutical Sciences. 64, #2 p 181, Feb. 1975.
NITS Technical Notes. No. 9, 1984, "Prodrugs based on phphospholipid-nucleoside conjugates" Springfield, VA, p. 630.
Stuttgart, De, geb. 1992; European J. of Pharmaceutics and Biopharmaceutics, 38(1):1-6. O. Vaizoglu et al., Jul. 26, 1989, EP-A-0325 160 (Hoechst A.G.).
Hostetler et al., Jun. 1991, "Phosphatidylaazothymidine. Mechanism of antiretroviral action in cem cells," J. Biol. Chem. 266(18):11714-11715.
Gusovsky et al., Feb. 1990, "Mechanism of maitotoxin-simulated phosphoinositide breakdown in HL-60 cells." J. Pharmacol. Ex. Ther. 252(2):469-470.
Govez-Cambronero et al., Apr. 1991, "Platelet-activating factor induces tyrosine phossssphorylation in human neutrophils." J. Biol. Chem. 266(10):6240-5.
Natarajan et al., "Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty acid hydroperoxide." J. Biol. Chem 268(2):930-7.
Coorssen et al., "GTP.gamma.S and phorbol ester act synergistically to stimulate both calcium independent secretion and phospholipase D activity in permeabilized human platerits. Inhibition by BAPTA and analogs" FEBS LETT. 316(2):170-4.
Duan et al., Feb. 1994, "Conversion to CA(2+)-independent form of Ca2+/calmodulin protein kinase II in rat pancreatic acini." Biochem. Biophys. Res. Commun. 199(1):368-373.
Hadad, S., et al., Pharmacokinetic Analysis and Anticonvulsant Activity of Two Polysteric Prodrugs of Valproic Acid, Biopharmaceutics & Drug Disposition, vol. 14, pp. 51-59 (1993).
Mergen, F., et al., Antiepileptic activity of 1,3-dihexadecanoylamino-2-valproyl-propan-2-ol, a Prodrug of Valproic Acid Endowed with a Tropism for the Central Nervous System, J. Pharm.Pharmacol., vol. 43, pp. 815-816 (1991).
D-Pharm Ltd.
Kishore Gollamudi S.
LandOfFree
Prodrugs with enhanced penetration into cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs with enhanced penetration into cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs with enhanced penetration into cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1964171